Brand-Name Drug Makers Win Key Provisions In Central American Free-Trade Pact

Law360, New York (July 4, 2005, 12:00 AM EDT) -- U.S. brand-name drug makers appear to have scored a major victory with the pharmaceutical provisions of the Central American Free Trade Agreement, which would provide five years of market exclusivity to new drugs.

The requirement gives brand-name manufacturers market exclusivity for five years after a drug is registered in the countries covered by the agreement, even if the 20-year patent has expired.

A similar five-year period exists in the U.S., but the trade agreement would require countries to enforce the five-year period even if the exclusivity...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.